|
86 Companies |
|
137 Products |
|
137 Products |
|
85 Mechanisms of Action |
|
4 Trials |
|
2019 News |
|
| «12...1617181920212223242526...3940» |
- Trial primary completion date: Past Pain Experience and Perception of Experimental Pain (clinicaltrials.gov) - May 12, 2014
P=N/A, N=92, Completed, Sponsor: Centre Hospitalier Esquirol
Trial primary completion date: Mar 2014 --> Jan 2014
- Trial completion date: Past Pain Experience and Perception of Experimental Pain (clinicaltrials.gov) - May 12, 2014
P=N/A, N=92, Completed, Sponsor: Centre Hospitalier Esquirol
Trial primary completion date: Mar 2014 --> Jan 2014 Trial completion date: Sep 2014 --> Jan 2014
- | olanzapine / Generic mfg.
New P4 trial: Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia (clinicaltrials.gov) - May 12, 2014
P4, N=64, Completed, Sponsor: CJ HealthCare Corporation
- Trial completion: Behavior During Experimentally Induced Pain (clinicaltrials.gov) - May 12, 2014
P=N/A, N=15, Completed, Sponsor: Centre Hospitalier Esquirol
Trial completion date: Sep 2014 --> Jan 2014 Active, not recruiting --> Completed
- Trial completion: Past Pain Experience and Perception of Experimental Pain (clinicaltrials.gov) - May 12, 2014
P=N/A, N=92, Completed, Sponsor: Centre Hospitalier Esquirol
Active, not recruiting --> Completed Recruiting --> Completed
- aripiprazole / Generic mfg., olanzapine / Generic mfg.
Trial primary completion date, Adherence: Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics. (clinicaltrials.gov) - May 11, 2014
P=N/A, N=100, Recruiting, Sponsor: North Shore Long Island Jewish Health System
Recruiting --> Completed Trial primary completion date: Dec 2013 --> Dec 2014
- Trial primary completion date: Supported Employment: Motivational Enhancement for Entry and Outcome (clinicaltrials.gov) - May 11, 2014
P2, N=150, Active, not recruiting, Sponsor: Department of Veterans Affairs
Trial primary completion date: Dec 2013 --> Dec 2014 Trial primary completion date: Feb 2014 --> May 2014
- aripiprazole / Generic mfg., olanzapine / Generic mfg.
Trial completion date, Adherence: Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics. (clinicaltrials.gov) - May 11, 2014
P=N/A, N=100, Recruiting, Sponsor: North Shore Long Island Jewish Health System
Trial primary completion date: Feb 2014 --> May 2014 Trial completion date: Dec 2013 --> Jan 2015
- Trial completion date: Supported Employment: Motivational Enhancement for Entry and Outcome (clinicaltrials.gov) - May 11, 2014
P2, N=150, Active, not recruiting, Sponsor: Department of Veterans Affairs
Trial completion date: Dec 2013 --> Jan 2015 Trial completion date: Feb 2014 --> Sep 2014
- || Trial primary completion date: HOSPIPalm: A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital Setting (clinicaltrials.gov) - May 8, 2014
P4, N=450, Recruiting, Sponsor: Janssen-Cilag International NV
Trial completion date: Feb 2014 --> Sep 2014 Trial primary completion date: Nov 2014 --> Aug 2014
- ||| Trial initiation date: HOSPIPalm: A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital Setting (clinicaltrials.gov) - May 8, 2014
P4, N=450, Recruiting, Sponsor: Janssen-Cilag International NV
Trial primary completion date: Nov 2014 --> Aug 2014 Initiation date: May 2013 --> Mar 2013
- || Trial completion date: HOSPIPalm: A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital Setting (clinicaltrials.gov) - May 8, 2014
P4, N=450, Recruiting, Sponsor: Janssen-Cilag International NV
Initiation date: May 2013 --> Mar 2013 Trial completion date: Nov 2014 --> Aug 2014
- Trial completion date: Life Goals Behavioral Change to Improve Outcomes for Veterans With Serious Mental Illness (clinicaltrials.gov) - May 5, 2014
P=N/A, N=55, Active, not recruiting, Sponsor: Department of Veterans Affairs
Trial completion date: Nov 2014 --> Aug 2014 Trial completion date: Mar 2014 --> Mar 2015
- || Trial primary completion date: The Management of Schizophrenia in Clinical Practice (MOSAIC) (clinicaltrials.gov) - May 4, 2014
P=N/A, N=557, Active, not recruiting, Sponsor: Genentech
Trial completion date: Mar 2014 --> Mar 2015 Trial primary completion date: Sep 2018 --> May 2014
- | Trial completion date: The Management of Schizophrenia in Clinical Practice (MOSAIC) (clinicaltrials.gov) - May 4, 2014
P=N/A, N=557, Active, not recruiting, Sponsor: Genentech
Trial primary completion date: Sep 2018 --> May 2014 Trial completion date: Sep 2018 --> May 2014
- ||| Abilify Maintena (aripiprazole depot formulation) / Otsuka, Lundbeck
Clinical: ReLiAM: Real Life Assessment of Abilify Maintena (clinicaltrials.gov) - May 4, 2014
P=N/A, N=252, Recruiting, Sponsor: Lundbeck Canada Inc.
- Trial primary completion date: Individually Based Psychosocial Rehabilitation for Older People With Serious Mental Illness (SMI) (clinicaltrials.gov) - May 4, 2014
P1, N=38, Completed, Sponsor: Dartmouth-Hitchcock Medical Center
Trial completion date: Sep 2018 --> May 2014 Trial primary completion date: Sep 2013 --> Dec 2013
- || Enrollment change: The Management of Schizophrenia in Clinical Practice (MOSAIC) (clinicaltrials.gov) - May 4, 2014
P=N/A, N=557, Active, not recruiting, Sponsor: Genentech
Trial primary completion date: Sep 2013 --> Dec 2013 N=2500 --> 557
- || Enrollment closed: The Management of Schizophrenia in Clinical Practice (MOSAIC) (clinicaltrials.gov) - May 4, 2014
P=N/A, N=557, Active, not recruiting, Sponsor: Genentech
N=2500 --> 557 Recruiting --> Active, not recruiting
- Trial completion: Individually Based Psychosocial Rehabilitation for Older People With Serious Mental Illness (SMI) (clinicaltrials.gov) - May 4, 2014
P1, N=38, Completed, Sponsor: Dartmouth-Hitchcock Medical Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- New P2 trial: EmeraldThunder: rTMS in First Episode Psychosis (clinicaltrials.gov) - May 4, 2014
P2, N=20, Recruiting, Sponsor: Indiana University
- ||| Enrollment open: An Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia (clinicaltrials.gov) - May 4, 2014
P=N/A, N=1500, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- Clinical: An Acceptance-Based Behavioral Intervention vs. Nutritional Counselling for Weight Loss in Psychotic Illness (clinicaltrials.gov) - May 2, 2014
P=N/A, N=12, Recruiting, Sponsor: Centre for Addiction and Mental Health
- | Abilify MyCite (aripiprazole tablets embedded with sensor) / Otsuka
Trial suspension, Adherence: Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder (clinicaltrials.gov) - Apr 30, 2014
P2, N=65, Suspended, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Active, not recruiting --> Recruiting Recruiting --> Suspended
- | omega-3 ethylester concentrate / Generic mfg.
Trial completion: Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia (clinicaltrials.gov) - Apr 28, 2014
P4, N=40, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Suspended Recruiting --> Completed
- | asenapine / Generic mfg.
Enrollment closed: Bioequivalence Fasting Study in Patients (clinicaltrials.gov) - Apr 27, 2014
P2/3, N=48, Active, not recruiting, Sponsor: Amneal Pharmaceuticals, LLC
Recruiting --> Completed Recruiting --> Active, not recruiting
- || Enrollment closed: An Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia (clinicaltrials.gov) - Apr 27, 2014
P=N/A, N=1433, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- minocycline / Generic mfg., clozapine / Generic mfg.
New P4 trial: Minocycline Augmentation to Clozapine (clinicaltrials.gov) - Apr 24, 2014
P4, N=35, Not yet recruiting, Sponsor: Emory University
- | paliperidone extended release / Generic mfg.
Trial initiation date: INVISION - An Observational Study to Explore Effectiveness, Tolerability and Safety of Paliperidone ER in Patients With Schizophrenia (clinicaltrials.gov) - Apr 23, 2014
P4, N=27, Completed, Sponsor: Janssen-Cilag B.V.
Recruiting --> Active, not recruiting Initiation date: Feb 2008 --> Mar 2008
- ||||| paliperidone extended release / Generic mfg.
Trial initiation date, Head-to-Head: A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia (clinicaltrials.gov) - Apr 23, 2014
P3, N=462, Completed, Sponsor: Janssen-Cilag International NV
Initiation date: Feb 2008 --> Mar 2008 Initiation date: Aug 2007 --> Oct 2007
- Trial completion: Peer Support for Increasing Physical Activity in People With Serious Mental Illnesses (clinicaltrials.gov) - Apr 22, 2014
P2, N=100, Completed, Sponsor: Johns Hopkins University
Initiation date: Aug 2007 --> Oct 2007 Recruiting --> Completed
- Risperdal Consta (risperidone depot formulation) / J&J
Trial initiation date: An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia (clinicaltrials.gov) - Apr 21, 2014
P4, N=640, Terminated, Sponsor: Xian-Janssen Pharmaceutical Ltd.
Recruiting --> Completed Initiation date: Dec 2006 --> Jan 2007
- Enrollment open: Remote Cognitive Remediation (clinicaltrials.gov) - Apr 21, 2014
P=N/A, N=100, Recruiting, Sponsor: Queen's University
Initiation date: Dec 2006 --> Jan 2007 Not yet recruiting --> Recruiting
- ||||| lurasidone / Generic mfg.
Enrollment closed: Lurasidone Low-Dose - High-Dose Study Study (clinicaltrials.gov) - Apr 20, 2014
P3, N=400, Active, not recruiting, Sponsor: Sunovion
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
Trial completion: Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia (clinicaltrials.gov) - Apr 20, 2014
P1, N=141, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Risperdal Consta (risperidone depot formulation) / J&J
Trial initiation date: A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode (clinicaltrials.gov) - Apr 17, 2014
P4, N=33, Completed, Sponsor: Janssen Cilag N.V./S.A.
Active, not recruiting --> Completed Initiation date: Mar 2006 --> Apr 2006
- ||| Patient reported outcomes: CIAS PRO: Schizophrenia Cognition Scale Development (clinicaltrials.gov) - Apr 17, 2014
P=N/A, N=125, Recruiting, Sponsor: New England Research Institutes
- |||| haloperidol / Generic mfg., lurasidone / Generic mfg.
Trial completion: A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia (clinicaltrials.gov) - Apr 15, 2014
P2, N=356, Completed, Sponsor: Sunovion
Initiation date: Mar 2006 --> Apr 2006 Active, not recruiting --> Completed
- |||| lurasidone / Generic mfg.
Trial completion: Safety and Tolerability Study of Drug to Treat Schizophrenia (clinicaltrials.gov) - Apr 15, 2014
P2, N=98, Completed, Sponsor: Sunovion
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Molecular Genetics of Schizophrenia (clinicaltrials.gov) - Apr 13, 2014
P=N/A, N=10800, Completed, Sponsor: NorthShore University HealthSystem
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Aristada once-monthly (aripiprazole lauroxil once-monthly formulation) / Alkermes
Trial completion: A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia (clinicaltrials.gov) - Apr 13, 2014
P3, N=623, Completed, Sponsor: Alkermes
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial initiation date: ACT-IP: Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis (clinicaltrials.gov) - Apr 10, 2014
P0, N=92, Not yet recruiting, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed Initiation date: Mar 2014 --> Aug 2014
- | Doria (risperidone extended release) / ROVI Pharmaceuticals Laboratories
Enrollment open: PRISMA-2: Pharmacokinetics and Tolerability Study of Risperidone ISM (clinicaltrials.gov) - Apr 10, 2014
P2, N=48, Recruiting, Sponsor: Rovi Pharmaceuticals Laboratories
Initiation date: Mar 2014 --> Aug 2014 Not yet recruiting --> Recruiting
- Daliresp (roflumilast) / AstraZeneca, Takeda, AbbVie
Enrollment open: Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia (clinicaltrials.gov) - Apr 10, 2014
P1, N=22, Recruiting, Sponsor: Takeda
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | NN1213 / Novo Nordisk
Trial completion: Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS) (clinicaltrials.gov) - Apr 9, 2014
P4, N=116, Completed, Sponsor: University of North Carolina, Chapel Hill
Not yet recruiting --> Recruiting No longer recruiting --> Completed
- Trial withdrawal: Sodium Benzoate for Treatment of Attenuated/Transient Psychosis. A Randomized Placebo-controlled Trial. (clinicaltrials.gov) - Apr 8, 2014
P2, N=0, Withdrawn, Sponsor: Niuvanniemi Hospital
No longer recruiting --> Completed Recruiting --> Withdrawn
- Enrollment change: Sodium Benzoate for Treatment of Attenuated/Transient Psychosis. A Randomized Placebo-controlled Trial. (clinicaltrials.gov) - Apr 8, 2014
P2, N=0, Withdrawn, Sponsor: Niuvanniemi Hospital
Recruiting --> Withdrawn N=140 --> 0
- ||| aripiprazole / Generic mfg., olanzapine / Generic mfg., haloperidol / Generic mfg.
Enrollment change: GiSAS: Pragmatic RCT Comparing Aripiprazole, Olanzapine and Haloperidol in the Treatment of Schizophrenia (clinicaltrials.gov) - Apr 8, 2014
P4, N=300, Completed, Sponsor: Mario Negri Institute for Pharmacological Research
N=140 --> 0 N=800 --> 300
- Clinical: Efficacy Study of GAÏA Program Cognitive Remediation of Facial Affects Processing in Schizophrenia (clinicaltrials.gov) - Apr 8, 2014
P=N/A, N=100, Recruiting, Sponsor: Hôpital le Vinatier
- |||||||||| Perseris (risperidone sustained-release 1-month depot) / Indivior, Reckitt Benckiser, HLS Therap
Clinical: Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients (clinicaltrials.gov) - Apr 8, 2014
P3, N=339, Recruiting, Sponsor: Reckitt Benckiser Pharmaceuticals Inc.